Fluorine-19 (19F) Labeled Benzothiazole Derivative as a Biosensor for detection of Alzheimer’s Disease using Magnetic Resonance Imaging
Yurii Shepelytskyi1, Michael G Campbell2,3, Francis T Hane2,3, Tao Li3, Vitalii Solomin4, Vira Grynko1, and Mitchell S Albert2,3,5
1Chemistry and Materials Science Program, Lakehead University, Thunder Bay, ON, Canada, 2Chemistry, Lakehead University, Thunder Bay, ON, Canada, 3Thunder Bay Regional Health Research Institute, Thunder Bay, ON, Canada, 4Enamine Ltd, Kyiv, Ukraine, 5Northern Ontario School of Medicine, Thunder Bay, ON, Canada
There are 5-7 million new cases of Alzheimer’s disease (AD) recorded each year worldwide. Typically, Positron Emission Tomography (PET) is used for the detection of amyloid b plaques allow for diagnosis of AD at early stages. However, PET has poor resolution in comparison to magnetic resonance imaging (MRI). The goal of the presented work was to demonstrate that an MR active derivative of the molecule Thioflavin-T, which contains 19F (2-[p-(Trifluoromethyl)phenyl]-1,3-benzothiazole (BTZ)), can be used to distinguish between samples of AD brains and healthy rat brains.
This abstract and the presentation materials are available to members only;
a login is required.